Annex 11 Is Changing: What Validation Teams Should Fix Before the Update Arrives

Annex 11 is no longer just a familiar compliance document sitting quietly in the background. The European Commission’s proposed revisions to EU GMP Annex 11 and the introduction of Annex 22 on Artificial Intelligence reflect a much bigger shift in pharmaceutical validation.

Modern regulated environments now rely on cloud systems, SaaS platforms, connected manufacturing, automated workflows, and AI-supported processes. Validation teams are no longer managing isolated systems with static documentation. They are managing dynamic digital ecosystems that constantly evolve.

The revised draft makes one thing very clear: validation is no longer a one-time project. Systems must remain in a validated state throughout their lifecycle. That means organizations need stronger lifecycle management, better traceability, continuous risk assessment, effective audit trail reviews, stronger supplier oversight, and more robust cybersecurity controls.

One of the biggest areas of focus is requirements management. Many companies still treat URS documents as project artifacts that become outdated over time. The new direction expects requirements to remain accurate, current, and aligned with the implemented system throughout its lifecycle.

Traceability is another major concern. Regulators increasingly expect organizations to maintain clear connections between requirements, risk assessments, testing, changes, deviations, and approvals. Static spreadsheets and disconnected documentation approaches are becoming harder to defend in modern inspections.

The draft also strengthens expectations around Quality Risk Management. Risk assessments are no longer meant to sit untouched after initial validation. Risk should actively guide testing depth, periodic reviews, access controls, audit trail reviews, supplier oversight, and revalidation decisions.

Cloud and SaaS oversight are also receiving increased attention. The revised draft emphasizes that outsourcing infrastructure or software does not outsource responsibility. Companies remain accountable for ensuring their systems stay compliant, secure, and inspection-ready even when vendors manage the platform.

Audit trails and access management are another major focus area. Regulators now expect audit trails to be not only present, but also reviewable, searchable, and practical for ongoing oversight. Shared accounts, excessive privileges, and weak access reviews are likely to receive greater scrutiny moving forward.

The proposed Annex 22 on AI adds another layer to this transformation. Organizations using AI in GMP environments will need governance frameworks covering intended use, model validation, performance monitoring, human oversight, change control, and data quality management.

All of this points toward a larger industry shift: moving from static validation packages toward continuous validation infrastructure. Many organizations are beginning to explore AI-Native Validation Infrastructure (ANVI) approaches that connect requirements, risks, testing, evidence, audit trails, and change management into a continuously controlled ecosystem rather than isolated documentation exercises.

The key message for validation teams is simple. Do not wait for the final publication before taking action. The direction of travel is already visible. Organizations that strengthen lifecycle management, traceability, supplier oversight, cybersecurity, and AI governance now will be far better positioned for the next era of digital validation.

👉 If you want to explore the full analysis, practical recommendations, and detailed breakdown of the Annex 11 revision, read the complete blog post on Validfor’s website.